Accelerating identification and regulatory approval of investigational cancer drugs

JAMA

Volumn 306, Issue 23, 2011, Pages 2608-2609

  Esserman, Laura J ^a   Woodcock, Janet ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURVIVAL; DRUG APPROVAL; DRUG RESPONSE; DRUG SCREENING; HIGH RISK PATIENT; NOTE; PREDICTION; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

EID: 84255183718     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.1837     Document Type: Note

References (9)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol. 2007;25(2):209-216. (Pubitemid 350003036)
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther. 2010;87(3):272-277.
3. National Health Expenditure Fact Sheet. Centers for Medicare & Medicaid Services. http://www.cms.gov/NationalHealthExpendData/. Accessed November 21, 2011.
4. Patlak M, Nass SJ, Balogh E. Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary. Washington, DC: National Academies Press; 2010.
5. I-SPY2 clinical trial. QuantumLeap Healthcare Collaborative. http://www .quantumleaphealth.org/?page-id=312. Accessed November 21, 2011.
6. Olson S, Berger AC. Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Product Development: Workshop Summary. Washington, DC: National Academies Press; 2011.
7. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009;86(1):97-100.
8. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-536.
9. Esserman LJ, Berry DA, Cheang MCU, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles. [published online December 15, 2011]. Breast Cancer Res Treat. doi:10.1007/sl0549-011-1895-2.